BIIB logo

Biogen Inc.

BIIB
Healthcare|Drug Manufacturers - General|US
$248.35
+4.42 (+1.81%)
DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82

Financials

Financial Snapshot

Market Cap
$36.71B
Enterprise Value
$43.21B
Revenue (TTM)
$10.30B
Net Income (TTM)
$348.0M
Cash & Investments
$1.30B
Net Cash
-$6.50B
Free Cash Flow (TTM)
$2.34B
Operating CF (TTM)
$2.25B
Debt/Equity
0.41

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$4.90B$3.69B$3.54B$4.48B$2.61B$3.80B$4.89B$1.05B$2.38B$3.82B$1.30B
Operating Cash Flow
$4.52B$4.55B$6.19B$7.08B$4.23B$3.64B$1.38B$1.55B$2.88B$2.20B$2.25B
Free Cash Flow
$3.86B$3.68B$5.30B$6.56B$3.81B$3.38B$1.14B$1.24B$2.52B$2.05B$2.34B
Capital Expenditure
-$616.1M-$867.4M-$770.6M-$514.5M-$424.8M-$258.1M-$240.3M-$311.4M-$359.8M-$153.8M$95.6M
Financing Cash Flow
-$987.8M-$2.38B-$4.47B-$5.86B-$5.27B-$2.09B-$1.76B$137.0M-$683.5M-$301.9M$776.6M

R&D Spending

R&D (TTM)
$2.15B
R&D Intensity
20.9%
R&D Growth vs Prior
+10.1%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$11.45B$12.27B$13.45B$14.38B$13.44B$10.98B$10.17B$9.84B$9.68B$9.81B$10.30B
R&D Expense
$1.97B$2.37B$2.71B$2.77B$4.53B$3.40B$2.60B$2.70B$2.49B$1.95B$2.15B
R&D % of Revenue
17.2%19.3%20.1%19.3%33.7%31.0%25.5%27.5%25.7%19.9%20.9%
SG&A
$1.95B$1.94B$2.11B$2.36B$2.52B$2.68B$2.41B$2.50B$2.39B$2.43B$2.75B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$11.45B$12.27B$13.45B$14.38B$13.44B$10.98B$10.17B$9.84B$9.68B$9.81B$10.30B
Cost of Revenue
$1.43B$1.63B$1.82B$1.96B$1.81B$2.11B$2.28B$2.53B$2.31B$2.90B$3.08B
Gross Profit
$10.02B$10.64B$11.64B$12.42B$11.64B$8.87B$7.90B$7.30B$7.37B$6.91B$7.21B
R&D
$1.97B$2.37B$2.71B$2.77B$4.53B$3.40B$2.60B$2.70B$2.49B$1.95B$2.15B
SG&A
$1.95B$1.94B$2.11B$2.36B$2.52B$2.68B$2.41B$2.50B$2.39B$2.43B$2.75B
Operating Income
$5.15B$5.35B$5.89B$7.04B$4.59B$2.79B$2.89B$2.10B$2.49B$1.88B$786.9M
Interest Expense
$260.0M$250.8M$200.6M$187.4M$222.5M$253.6M$246.6M$246.9M$250.3M$246.0M$304.9M
Pretax Income
$4.93B$5.13B$5.90B$7.05B$5.05B$1.78B$3.59B$1.30B$1.91B$1.40B$290.1M
Net Income
$3.70B$2.54B$4.43B$5.89B$4.00B$1.56B$3.05B$1.16B$1.63B$1.29B$348.0M
EPS (Diluted)
16.9311.9221.5831.4224.8010.4020.877.9711.198.832.34
EBITDA
$6.39B$6.61B$7.01B$7.74B$5.11B$3.92B$3.54B$2.38B$3.00B$2.95B$1.45B
Shares Out. (M)
218.80213.00205.30187.40161.30149.60146.00145.60145.90146.70147.80

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$2.33B$1.57B$1.22B$2.91B$1.33B$2.26B$3.42B$1.05B$2.38B$3.01B$1.30B
Short-Term Investments
$2.57B$2.12B$2.31B$1.56B$1.28B$1.54B$1.47B$0.00$0.00$807.2M$0.00
Total Current Assets
$8.73B$7.87B$7.64B$8.38B$6.89B$7.86B$9.79B$6.86B$7.46B$8.97B$7.58B
Total Assets
$22.88B$23.65B$25.29B$27.23B$24.62B$23.88B$24.55B$26.84B$28.05B$29.44B$32.05B
Total Current Liabilities
$3.42B$3.37B$3.30B$4.86B$3.74B$4.30B$3.27B$3.43B$5.53B$3.35B$3.90B
Long-Term Debt
$6.51B$5.93B$5.94B$4.46B$7.43B$6.27B$6.28B$6.79B$4.55B$6.58B$7.29B
Total Liabilities
$10.75B$11.05B$12.26B$13.90B$13.93B$12.92B$11.17B$12.05B$11.33B$11.18B$13.13B
Stockholders' Equity
$12.14B$12.61B$13.04B$13.34B$10.70B$10.90B$13.40B$14.80B$16.72B$18.26B$18.92B
Retained Earnings
$15.07B$15.81B$16.26B$16.46B$13.98B$13.91B$16.47B$17.63B$19.26B$20.55B$20.95B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$4.52B$4.55B$6.19B$7.08B$4.23B$3.64B$1.38B$1.55B$2.88B$2.20B$2.25B
Capital Expenditure
-$616.1M-$867.4M-$770.6M-$514.5M-$424.8M-$258.1M-$240.3M-$311.4M-$359.8M-$153.8M$95.6M
Free Cash Flow
$3.86B$3.68B$5.30B$6.56B$3.81B$3.38B$1.14B$1.24B$2.52B$2.05B$2.34B
Investing Cash Flow
-$2.48B-$2.96B-$2.05B$470.5M-$608.6M-$563.7M$1.59B-$4.09B-$799.2M-$1.37B-$5.50B
Financing Cash Flow
-$987.8M-$2.38B-$4.47B-$5.86B-$5.27B-$2.09B-$1.76B$137.0M-$683.5M-$301.9M$776.6M
Issuance of Stock
$43.7M-$5.3M-$2.1M$0.00-$4.6M-$700.0K-$1.9M-$44.3M-$31.3M-$10.0M$6.2M
Repurchase of Stock
-$1.00B-$1.37B-$4.35B-$5.87B-$6.68B-$1.80B-$750.0M$0.00$0.00$0.00$0.00
Net Debt Issuance
-$2.7M-$560.9M-$3.2M$0.00$1.47B-$170.0M-$1.00B$187.3M-$650.0M-$16.9M-$400.0M
Stock Based Comp.
$154.8M$128.0M$157.5M$182.3M$198.3M$238.6M$254.1M$264.2M$291.2M$290.8M$141.1M
Net Change in Cash
$1.02B-$752.7M-$349.2M$1.69B-$1.58B$930.2M$1.16B-$2.37B$1.33B$633.5M-$2.51B

Dilution Tracker

Shares Outstanding
148M
5-Year Share Growth
-9.1%
Stock Issuance (TTM)
$6.2M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
218.80213.00205.30187.40161.30149.60146.00145.60145.90146.70147.80
Change vs Prior %
—-2.7%-3.6%-8.7%-13.9%-7.3%-2.4%-0.3%0.2%0.5%0.7%
Stock Issuance
$43.7M-$5.3M-$2.1M$0.00-$4.6M-$700.0K-$1.9M-$44.3M-$31.3M-$10.0M$6.2M
Stock Repurchase
-$1.00B-$1.37B-$4.35B-$5.87B-$6.68B-$1.80B-$750.0M$0.00$0.00$0.00$0.00
Stock Based Comp.
$154.8M$128.0M$157.5M$182.3M$198.3M$238.6M$254.1M$264.2M$291.2M$290.8M$141.1M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
87.5%86.7%86.5%86.4%86.6%80.8%77.6%74.2%76.1%70.5%70.0%
Operating Margin %
45.0%43.6%43.8%49.0%34.2%25.4%28.4%21.3%25.7%19.1%7.6%
Net Margin %
32.3%20.7%32.9%41.0%29.8%14.2%29.9%11.8%16.9%13.2%3.4%
EBITDA Margin %
55.8%53.8%52.1%53.8%38.0%35.7%34.8%24.2%31.0%30.0%14.1%
FCF Margin %
33.7%30.0%39.4%45.7%28.3%30.8%11.2%12.6%26.0%20.9%22.8%
ROE %
30.5%20.1%34.0%44.1%37.4%14.3%22.7%7.8%9.8%7.1%1.9%
ROA %
16.2%10.7%17.5%21.6%16.3%6.5%12.4%4.3%5.8%4.4%1.1%
ROIC %
19.8%13.7%20.3%24.7%17.7%13.2%11.2%8.0%8.8%6.6%2.8%
R&D / Revenue %
17.2%19.3%20.1%19.3%33.7%31.0%25.5%27.5%25.7%19.9%20.9%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
6.4%7.2%9.6%6.9%-6.5%-18.3%-7.4%-3.3%-1.6%1.4%
Gross Profit
5.2%6.3%9.3%6.8%-6.3%-23.8%-11.0%-7.5%0.9%-6.1%
Operating Income
5.3%3.8%10.2%19.6%-34.8%-39.2%3.5%-27.4%18.7%-24.6%
Net Income
4.4%-31.4%74.5%32.9%-32.1%-61.1%95.8%-61.9%40.6%-20.8%
EPS (Diluted)
10.4%-29.6%81.0%45.6%-21.1%-58.1%100.7%-61.8%40.4%-21.1%
Operating Cash Flow
21.7%0.6%36.0%14.4%-40.2%-13.9%-62.0%11.8%85.9%-23.3%
Free Cash Flow
25.6%-4.6%43.9%23.8%-42.0%-11.1%-66.2%8.0%103.6%-18.5%
R&D Expense
-2.0%20.3%14.2%2.2%63.5%-24.9%-23.6%4.1%-7.9%-21.5%
SG&A Expense
-7.7%-0.7%8.9%11.8%6.6%6.5%-10.1%3.9%-4.6%2.0%
Total Assets
17.3%3.4%6.9%7.7%-9.6%-3.0%2.8%9.3%4.5%5.0%
Book Value / Share
36.7%6.7%7.3%12.1%-6.8%10.7%25.4%11.0%12.2%8.5%
Debt
-0.1%-8.9%-0.0%7.3%22.9%-2.9%-13.0%10.9%-9.6%4.8%
Diluted Shares
-5.4%-2.7%-3.6%-8.7%-13.9%-7.3%-2.4%-0.3%0.2%0.5%

Valuation

P/E (TTM)105.23
10Y Low / Med / High9.43 / 16.72 / 32.27
P/S3.57
10Y Low / Med / High2.30 / 3.86 / 5.52
P/B1.94
10Y Low / Med / High1.33 / 3.68 / 5.37
EV/EBITDA29.83
10Y Low / Med / High7.62 / 10.35 / 18.40
EV/Revenue4.20
10Y Low / Med / High2.74 / 4.27 / 5.87
P/FCF15.67
10Y Low / Med / High8.46 / 12.59 / 35.17

Intrinsic Value Models (per share)

DCF Value
$517.66
Graham Number
$82.35
Cash / Share
$8.82
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
16.7226.6813.929.439.8522.9813.2132.2713.6519.89105.23
P/S Ratio
5.415.524.583.862.933.263.963.812.302.633.57
P/B Ratio
5.105.374.734.163.683.283.002.531.331.411.94
EV/EBITDA
10.3510.919.467.628.9810.4812.2818.408.8610.1029.83
EV/Revenue
5.785.874.934.103.413.744.274.452.743.034.20

Analyst Estimates & Quality

Altman Z-Score
3.11
Safe
Piotroski F-Score
5
Moderate

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$10.58B$10.78B$11.13B
Net Income$1.86B$2.41B$2.71B
EPS$12.49$16.22$18.34
# Analysts (EPS)192111

Revenue Segments

By Product

Segment202020212022202320242025
Fumarate$3.91B$2.36B$2.00B$1.59B$1.60B$1.43B
Interferon$1.88B$1.57B$1.31B$1.11B$968.0M$945.6M
MS Product Revenues$7.83B$6.10B$5.43B$4.66B$4.35B$4.04B
SPINRAZA$2.05B$1.91B$1.79B$1.74B$1.57B$1.55B
TYSABRI product$1.95B$2.06B$2.03B$1.88B$1.72B$1.67B

By Geography

Segment202020212022202320242025
Non-US$4.79B$5.04B$4.52B—$3.98B$3.57B
UNITED STATES$5.90B$3.81B$3.47B$3.14B$3.24B$2.37B
Asia———$649.4M——
Europe———$2.13B——
GERMANY———$868.0M——